Globe Newswire (Wed, 27-May 8:45 AM ET)
Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results
Globe Newswire (Fri, 15-May 7:00 AM ET)
Traws Pharma Accelerates Clinical Development Against Deadly Hantavirus Threat
Market Chameleon (Mon, 11-May 6:31 AM ET)
Traws Pharma Targets Hantavirus Threat with Advanced Clinical Candidates
Market Chameleon (Fri, 8-May 5:54 AM ET)
Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections
Globe Newswire (Fri, 8-May 7:30 AM ET)
Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights
Globe Newswire (Wed, 15-Apr 4:01 PM ET)
Traws Pharma Announces Up to $60 Million Private Placement Financing
Globe Newswire (Wed, 15-Apr 8:15 AM ET)
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.
Traws Pharma trades on the NASDAQ stock market under the symbol TRAW.
As of June 5, 2026, TRAW stock price declined to $1.37 with 352,218 million shares trading.
TRAW has a beta of -0.11, meaning it tends to be less sensitive to market movements. TRAW has a correlation of 0.00 to the broad based SPY ETF.
TRAW has a market cap of $20.76 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that TRAW belongs to (by Net Assets): VXF.
TRAW has underperformed the market in the last year with a price return of -7.4% while the SPY ETF gained +25.6%. TRAW has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -14.4% and -8.1%, respectively, while the SPY returned +8.5% and -1.1%, respectively.
TRAW support price is $1.34 and resistance is $1.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TRAW shares will trade within this expected range on the day.
